Navigation Links
Tamoxifen Speeds Diagnosis of ER-Negative Breast Cancer
Date:10/7/2008

Study suggests the drug may make tumors easier to spot

TUESDAY, Oct. 7 (HealthDay News) -- A treatment that helps prevent one type of breast cancer in women with an evaluated risk of the disease also appears to help doctors make an earlier diagnosis of another form of breast cancer, a new study reports.

Tamoxifen previously had been shown to reduce the risk of estrogen receptor (ER) positive breast cancer in women at high risk of the disease, but not to affect the chance of developing ER-negative disease.

However, the study by researchers at the University of Texas M.D. Anderson Cancer Center in Houston found that the treatment helped doctors diagnosis women who later developed estrogen receptor (ER) negative breast cancer an average of one year sooner than the same at-risk patients who instead took a placebo.

For the study, 13,388 women at high risk of breast cancer participated in the trial; 174 women were diagnosed with ER-positive tumors and 69 women with ER-negative tumors. The median time to diagnosis for ER-negative disease was 36 months in the placebo group but only 24 months in the tamoxifen group.

The median time to diagnosis for ER-positive disease was similar in the placebo and tamoxifen groups at 43 and 51 months, respectively, which is not statistically different.

It's not clear why the diagnosis time of ER-negative tumors is so different, but the authors hypothesized that the drug may make the tumors more detectable. No evidence was found that tamoxifen altered the growth rate of ER-negative disease.

The study was published online Oct. 7 in the Journal of the National Cancer Institute.

The findings should be investigated further, the researchers concluded.

More information

The National Cancer Institute has more about tamoxifen.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, Oct. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Future hope for patients with breast cancers resistant to tamoxifen
2. New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers
3. Acupuncture relieves hot flushes in breast cancer patients taking tamoxifen
4. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
5. Chemotherapy and tamoxifen reduce risk of second breast cancer
6. Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
7. Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
8. Tamoxifen Helps Treat Bipolar Disorder
9. New Technology Speeds GI Disease Diagnosis
10. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
11. DDT Compound Speeds Breast Cancer Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Webster-Calhoun Cooperative Telephone Association (WCCTA) has sent out notices ... March 14th at 7:00 pm at the Southeast Valley High School Gymnasium located in Gowrie, ... Service" What do you look for in a company when you purchase a ...
(Date:2/28/2017)... ... 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud ... 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has provided the ... Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products and services. ...
(Date:2/28/2017)... Chicago, IL (PRWEB) , ... February 28, 2017 ... ... on Tuesday, March 7, 2017, from 4:30-5:30 p.m. at the 11th Annual RISE ... Stars, quality management, financial compliance, performance analytics, and engagement strategies. , The discussion ...
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata Ananda ... Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally tailored ... customized retreats offer the winter-weary soul an excellent opportunity to come out of ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Pharmaceuticals, Inc. (Nasdaq: IONS ) today reported ... with pro forma operating income of $25.8 million and ... The Company also reported a GAAP loss from operations ... of significant accomplishments for Ionis, culminating in the U.S. ... very broad label. The approval of SPINRAZA is a ...
(Date:2/28/2017)... , Feb. 28, 2017 Prepacked ... and biotechnology industry, food and beverage industry, ... research institutes, and analytical laboratories. Acceptance of ... in the pipelines of pharma companies are ... prepacked chromatography columns market. Increasing research and ...
(Date:2/28/2017)... , Feb. 27, 2017  Titan Pharmaceuticals, ... for the treatment of select chronic diseases utilizing ... announced that the U.S. Food & Drug Administration ... ropinirole implant Investigational New Drug Application (IND) and ... the clinical study pending submission of the requested ...
Breaking Medicine Technology: